CoChat
Sign Up
Cited by 672Immunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

The role of CD4+ T cell responses in antitumor immunity

Open access
Pardoll, Drew M, Topalian, Suzanne L·1998·Current Opinion in Immunology
DOI 10.1016/s0952-7915(98)80228-8
Open this paper in CoChat — free accountOpen PDF

Abstract

While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses, recent evidence indicates that CD4+ T cells are an equally critical component of the antitumor immune response. Successful immunity to cancer will therefore require activation of tumor-specific CD4+ T cells. Tumor antigens recognized by CD4+ T cells that are restricted by MHC class II are beginning to be defined in both murine and human tumors. These will provide the basis for new generations of antigen-specific tumor vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0952-7915(98)80228-8

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The presence of tumor-infiltrating CD8+ T cells and the production of Th1 cytokines within tumors are correlated with favorable prognoses in overall survival and disease-free survival across various malignancies.

    “The presence of tumor-infiltrating CD8+ T cells and the production of Th1 cytokines within tumors have been correlated with favorable prognoses in terms of overall survival and disease-free survival across various malignancies [11,12,13,14].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [13]

    The Introduction discusses CD8+ T cells in antitumor immunity, and ‘The role of CD4+ T cells in productive antitumor immunity’ discusses Th1 effector pathways. Neither section reports a correlation between tumor-infiltrating CD8+ T cells or intratumoral Th1 cytokines and overall or disease-free survival. Searches for the prognostic and survival terms did not locate such a finding in our copy; page numbers were not available. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

  • Regulatory T cells, a subset of CD4+ T cells, accumulate in the tumor microenvironment and contribute to immune escape mechanisms.

    “Furthermore, regulatory T cells (Treg), a subset of CD4+ T cells, accumulate in the tumor microenvironment, contributing to immune escape mechanisms [79].”

    From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [79]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 44

  1. Riddell SR, Greenberg PD: Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immuno/1995, 13:545-586.
  2. Noguchi Y, Richards EC, Chen YT, Old I_J: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Nat/Acad Sci USA 1995, 92:2219-2223.
  3. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, Ter Schegget J, Melief C J, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur J Immuno/1993, 23:2242-2249.
  4. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995, 1:1179-1183.
  5. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLeo AB: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995, 1:1297-1302.
  6. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Ce//1990, 60:397-403.
  7. Golumbek PT, Lazenby A J, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991, 254:713-716.
  8. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine grsnulocyte- macrophage c01ony-stimulating factor stimulates potent, specific, long-lasting anti-tumor immunity. Proc Nat/Acad Sci USA 1993, 90:3539-3543.
  9. Lin KY, Guarnieri FG, Staveley-O'Carroll K, Levitsky HI, August JT, Pardoll DM, Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
  10. Levitsky HI, Lazenby A, Hayashi R J, Pardoll DM: In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994, 179:1215-1224.
  11. Ostrand-Rosenberg S: Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immuno/1994, 6:722-727.
  12. Pulaski BA, McAdam A J, Hutter EK, Biggar S, Lord EM, Frelinger JG: Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4+-dependent mechanism. Cancer Res 1993, 53:2112-2117.
  13. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G: Role of neutrophils and CD4 + T lymphocytas in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992, 149:3627-3635.
  14. Hock H, Dorsch M, Diamantstein T, Blankenstein T: Interleukin 7 induces CD4 + T cell-dependent tumor rejection. J Exp Med 1991, 174:1291-1298.
  15. Pan ZK, Ikoncmidis G, Pardoll D, Paterson Y: Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res 1995, 55:4776-4779.
  16. Greenberg PD, Kern DE, Cheever MA: Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-l+,2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985, 161:1122-1134.
  17. Matis LA, Ruscetti SK, Longo DL, Jacobson S, Brown El, Zinn S, Kruisbeek AM: Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4 + clones and Lyt-2 + cytoiytic clones which recognize a tumor-specific cell surface antigen. J Immunol 1986, 135:703-713.
  18. Bookman MA, Swerdlow R, Matis LA: Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol 1987, 139:3166-3170.
  19. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borello I, Hwang L, Fein S, Pardoll D, Levitsky H: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Nat/Acad Sci USA 1998, 95:1178-1183.
  20. Adler A J, Marsh DW, Yochum GS, Guzzo JL, Nigam A, Nelson WG, Pardoll DM: CD4 + T cell tolerance to parenchymal serf-antigens requires presentation by bone marrow-derived antigen- presenting cells../Exp Med 1998, 187:1555-1564.
  21. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T: B cells • inhibit induction of T cell-dependent tumor immunity. Nat Med 1998, 4:627-630.
  22. Schoenberger SP, Toes REM, Van der Voort EIH, Offringa R, • Melief CJM: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1996, 393:480-483. References ["-26"] provide evidence that CD4 + T cell help, for the gen- eration of cytotoxic T lymphocytes (CTLs), occurs through the antigen-presenting cell (APC) as an intermediary. Activated CD4 + T cells provide signals, through interactions of CD40 ligand and CD40, to APCs which condition them to develop the capability to prime CD8 + CTLs.
  23. Bennett SR, Carbone FR, Karamalis R, Flavell RA, Miller JFAP, • Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:4?8-480. References ["-26"] provide evidence that CD4 + T cell help, for the gen- eration of cytotoxic T lymphocytes (CTLs), occurs through the antigen-presenting cell (APC) as an intermediary. Activated CD4 + T cells provide signals, through interactions of CD40 ligand and CD40, to APCs which condition them to develop the capability to prime CD6 + CTLs.
  24. Ridge JP, DiRosa F, Matzinger P: A conditioned dendritic cell can be • a temporal bridge between a CD4 + T-helper and a T-killer cell. Nature 1998, 393:474-478. References ["-26"] provide evidence that CD4 + T cell help, for the gen- eration of cytotoxic T lymphocytes (CTLs), occurs through the antigen-presenting cell (APC) as an intermediary. Activated CD4 + T cells provide signals, through interactions of CD40 ligand and CD40, to APCs which condition them to develop the capability to prime CD8 + CTLs.
  25. ?. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264:961-965.
  26. Topalian SL: MHC class II restricted tumor antigens and the role of CD4 + T cells in cancer immunotherapy. Curt Opin Immunol 1994, 6:741 -?45.
  27. Heike M, Schlaak J, Schulze-Bergkamen H, Heyl S, Herr W, Schmitt U, Schneider PM, Meyer zum Buschenfelde KH: SpecifidUes and functions of CD4 + H LA class I I-restricted T call clones against a human sarcoma. J/mmunol 1996, 156:2205-2213.
  28. Heike M, Ouchmann R, May E, Schultze-Bergkamen H, Schmitt U, Meyer zum Buschenfelde KH: Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4 + HLA-DR-restricted T calls suggest a limited set of immunodominant sarcoma antigens. Int J Cancer 1997, 72:403-407.
  29. De Gruijl TD, Bontkes H J, Walboomers JMM, Stukart M J, Doekhie FS, Remmink A J, Helmerhorst TJM, Verheijen RHM, Duggan-Keen MF, Stern PL et al.: Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998, 58:1700-1706.
  30. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace D J, Cheerer MA: CD4 + T-cell immunity to mutated ms protein in pancreatic and colon cancer patients. Cancer Res 1995, 55:2984-298?.
  31. Nakao M, Sata M, Saitsu H, Yutani S, Kawamoto M, Kojiro M, Itoh K: CD4 + hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma. Ce//Immuno/1997, 177:176-181.
  32. Okada K, Yasumura S, Muller-Fleckenstein I, Fleckenstein B, Talib S, Koldovsky U, Whiteside TL: Interactions between autologous CD4 + and CD8 + T lymphocytes and human squamous cell carcinoma of the head and neck. Cel/Immunol 1997, 177:35-48.
  33. ?. Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G: CharacterisaUon of immune responses in pancreatic carcinoma patients with mutant p21 res pepUde vaccination. Brit .I Cancer 1996, 74:1828-1833.
  34. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with pepUde-or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
  35. Ellern KA, O'Rourke MG, Johnson GR, Parry G, Misko IS, Schmidt CW, Parsons PG, Burrows SR, Cross S, Fell A eta/.: A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulaUng-factor- transduced autologous melanoma cells for immunotherapy. Cancer/mrnunol/mmunother 1997, 44:10-20.
  36. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA: Human CD4 + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Nat/Acad Sci USA 1994, 91:9461-9465.
  37. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF: Melanoma-specific CD4 + T cells recognize nonmutated HLA-DR-rastricted tyrosinase epitopes. .I Exp Med 1996, 183:1965-1971.
  38. Monach PA, Meredith SC, Siegel CT, Schreiber H: A unique tumor antigen produced by a single amino acid substitution. Immunity 1995, 2:45-59.
  39. Chikamatsu K, DeLeo AB, Whiteside TL: Analysis of HLA-DR4- restricted tumor antigens recognized by CD4 + T lymphocytes. Proc Amer Assoc Cancer Res 1998, 39:261.
  40. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H: Isolation of novel HI.A-DR restricted potential tumor- associated antigens from the melanoma cell line FM3. Cancer Res 1997, 57:3238-3244.
  41. Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild Hi, Stenner F, Seitz G, Rammensee HG, Pfreundschuh M: The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996, 56:4766-4772.
  42. Chen YT, Scanlan M.I, Sahin U, Tureci O, Gure AO, Tsang S, Williarnson B, Stockert E, Pfreundschuh M, Old I1: A tesUcular antigen aberrently expressed in human cancers detected by autologous antibody screening. Proc Nat/Acad Sci USA 1997, 94:1914-1918.
  43. lager E, Chen YT, Drijfhout ,lW, Karbach .I, Ringhoffer M, .lager D, Arand M, Wada H, Noguchi Y, Stockert E et al.: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1 : definition of human histocompaUbility leukocyte antigen (HLA)-A2-binding peptide epitopes../Exp Med 1998, 187:265-270.
  44. lager E, .lager D, Karbach ,l, Zidianakis Z, Knuth A: Simultaneous humoral and cellular immune responses against 'cancer -testis' antigen NY-ESO-1 : implications for NY-ESO-l-specific immunotherepy. Proc Amer Assoc Cancer Res 1998, 39:368.

Cited by

Sorted by citations

Authors
Pardoll, D. M., & Topalian, S. L.
Affiliations
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
ORCID
Venue
Current Opinion in Immunology
Publisher
Elsevier BV
Published
1998-10
Volume
10
Issue
5
Pages
588-594
ISSN
0952-7915 (ISSN-L)
DOI
10.1016/s0952-7915(98)80228-8
OpenAlex
W2083500661
Cited by
672
References
0
Citations by year
2026: 6 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 22 · 2021: 15 · 2020: 25 · 2019: 15 · 2018: 13 · 2017: 19 · 2016: 10 · 2015: 21 · 2014: 21 · 2013: 20 · 2012: 17
FWCI
3.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Opinion in Immunology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
CD4+ T cells, antitumor immunity, tumor-specific T cells, MHC class II, tumor antigens, tumor immunology, T cell activation
MeSH terms
Animals, Histocompatibility Antigens Class II, Antigens, Neoplasm, Humans, Immune Tolerance, Neoplasms, CD4-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review